BioCorRx (OTC: BICX) Interview with CEO Brady Granier, discussing the company's technology for treating opioid, alcohol and other addictions with Naltrexone implants. Brady discusses the company's business model, progress towards FDA approval, and upcoming launch of a promising weight-loss program utilizing the Naltrexone implant.
. . .
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires June 15, 2019.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2